Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms: a Pragmatic Randomized Clinical Trial (DECISION)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk. This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• Patients with Suspected HF (Group S):

‣ Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).

⁃ Age over 65 years (i.e., 65 included).

⁃ Presence of symptoms and/or signs typical of Heart Failure (defined by the European Society of Cardiology, ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.

• Patients at Risk of Heart Failure due to the presence of cardiovascular (Group R):

‣ Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).

⁃ Age over 65 years (i.e., 65 included).

⁃ Absence of symptoms and/or signs typical of Heart Failure (defined by the ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.

⁃ Presence of at least 1 ACC/AHA Heart Failure risk factor, including hypertension, cardiovascular disease (atrial fibrillation, coronary heart disease or stroke), diabetes, obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or family history of cardiomyopathy that requires an ECG test for any reason in a primary care center or with an indication of a regular health examination where an ECG is included.

Locations
Other Locations
Spain
Hospital General Universitario Gregorio Marañón
NOT_YET_RECRUITING
Madrid
Hospital Universitario 12 de Octubre
RECRUITING
Madrid
Primary Care: Gerencia Asistencial Atención Primaria Madrid
RECRUITING
Madrid
Hospital Universitario Marqués de Valdecilla
NOT_YET_RECRUITING
Santander
Sweden
Region Stockholm
NOT_YET_RECRUITING
Stockholm
Contact Information
Primary
Juan Francisco Delgado Jiménez, MD, PhD
juan.delgado@salud.madrid.org
+34917792640
Time Frame
Start Date: 2025-07-23
Estimated Completion Date: 2025-12
Participants
Target number of participants: 1968
Treatments
Experimental: Experimental
AI-assisted ECG analysis via the Willem™ platform
No_intervention: Comparator
Standard ECG assessment
Related Therapeutic Areas
Sponsors
Collaborators: Fundación para la Investigación Biomédica del Hospital Gregorio Maranon, Karolinska Institutet, Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria de la Comunidad de Madrid (FIIBAP), Servicio Madrileno De Salud (SERMAS), Region Stockholm, AstraZeneca, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Instituto de Investigación Marqués de Valdecilla
Leads: Idoven 1903 S.L.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials